Wang Kehan
Hubei University of Chinese Medicine, Wuhan, Hubei, China.
Front Bioeng Biotechnol. 2025 Jul 23;13:1601673. doi: 10.3389/fbioe.2025.1601673. eCollection 2025.
Glioblastoma multiforme (GBM) is an exceedingly aggressive primary brain neoplasm characterized by a dismal prognosis owing to its invasiveness, heterogeneity, and immunity to conventional therapies. Conventional therapies, including surgery, chemotherapy, and radiotherapy, encounter constraints due to tumor evasion and physiological obstacles, such as the blood-tumor (BTB) and blood-brain barriers (BBB), which impact the treatment of GBM. Nanotechnology is employed to augment the permeability of anticancer agents through these barriers, thereby improving treatment efficacy and minimizing toxicity. Lipid-based nanoparticles, such as nanostructured lipid carriers (NLCs) and solid lipid nanoparticles (SLNs), offer drug encapsulation, stability, and controlled release, whereas metal nanoparticles, including gold and silver, augment imaging and photothermal therapy efficacy. This review investigates the traversal of nano carriers across the BBB and BTB, emphasizing the significance of dimensions, charge, and surface functionality, while underscoring the potential of nanotechnology in managing GBM. Advancements in nanomedicine possess the capacity to create more efficacious therapeutic strategies, markedly improving patient outcomes in the management of GBM.
多形性胶质母细胞瘤(GBM)是一种极具侵袭性的原发性脑肿瘤,因其侵袭性、异质性以及对传统疗法的免疫性而预后不佳。包括手术、化疗和放疗在内的传统疗法,由于肿瘤逃逸和生理障碍(如血瘤屏障(BTB)和血脑屏障(BBB))而受到限制,这些障碍影响了GBM的治疗。纳米技术被用于增强抗癌药物通过这些屏障的渗透性,从而提高治疗效果并将毒性降至最低。基于脂质的纳米颗粒,如纳米结构脂质载体(NLCs)和固体脂质纳米颗粒(SLNs),具有药物封装、稳定性和控释功能,而金属纳米颗粒,包括金和银,则可增强成像和光热治疗效果。本综述研究了纳米载体穿越血脑屏障和血瘤屏障的情况,强调了尺寸、电荷和表面功能的重要性,同时强调了纳米技术在治疗GBM方面的潜力。纳米医学的进展有能力创造更有效的治疗策略,显著改善GBM治疗中的患者预后。
Front Bioeng Biotechnol. 2025-7-23
Curr Cancer Drug Targets. 2025-6-30
ACS Appl Mater Interfaces. 2025-6-18
Int J Pharm. 2025-9-15
Antioxidants (Basel). 2025-3-18
Biomed Pharmacother. 2025-1
Beilstein J Nanotechnol. 2024-11-22
Int J Mol Sci. 2024-9-19
Int J Pharm X. 2024-8-28
Nanomaterials (Basel). 2024-8-31
Pharmaceuticals (Basel). 2024-8-15
Signal Transduct Target Ther. 2024-8-12